These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 35887049)

  • 1. Potential COVID-19 Therapies from Computational Repurposing of Drugs and Natural Products against the SARS-CoV-2 Helicase.
    Piplani S; Singh P; Winkler DA; Petrovsky N
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential phytochemical inhibitors of SARS-CoV-2 helicase Nsp13: a molecular docking and dynamic simulation study.
    Vivek-Ananth RP; Krishnaswamy S; Samal A
    Mol Divers; 2022 Feb; 26(1):429-442. PubMed ID: 34117992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying SARS-CoV-2 Drugs Binding to the Spike Fatty Acid Binding Pocket Using In Silico Docking and Molecular Dynamics.
    Piplani S; Singh P; Petrovsky N; Winkler DA
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computationally repurposed drugs and natural products against RNA dependent RNA polymerase as potential COVID-19 therapies.
    Piplani S; Singh PK; Winkler DA; Petrovsky N
    Mol Biomed; 2021; 2(1):28. PubMed ID: 34766004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
    Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
    Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Target identification for repurposed drugs active against SARS-CoV-2 via high-throughput inverse docking.
    Ribone SR; Paz SA; Abrams CF; Villarreal MA
    J Comput Aided Mol Des; 2022 Jan; 36(1):25-37. PubMed ID: 34825285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Silico Binding of 2-Aminocyclobutanones to SARS-CoV-2 Nsp13 Helicase and Demonstration of Antiviral Activity.
    Mohammad TSH; Gupta Y; Reidl CT; Nicolaescu V; Gula H; Durvasula R; Kempaiah P; Becker DP
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug repurposing against SARS-CoV-2 using computational approaches.
    Kumar S; Kovalenko S; Bhardwaj S; Sethi A; Gorobets NY; Desenko SM; Poonam ; Rathi B
    Drug Discov Today; 2022 Jul; 27(7):2015-2027. PubMed ID: 35151891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repurposing potential of posaconazole and grazoprevir as inhibitors of SARS-CoV-2 helicase.
    Abidi SH; Almansour NM; Amerzhanov D; Allemailem KS; Rafaqat W; Ibrahim MAA; la Fleur P; Lukac M; Ali S
    Sci Rep; 2021 May; 11(1):10290. PubMed ID: 33986405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19.
    Rai H; Barik A; Singh YP; Suresh A; Singh L; Singh G; Nayak UY; Dubey VK; Modi G
    Mol Divers; 2021 Aug; 25(3):1905-1927. PubMed ID: 33582935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting SARS-CoV-2 non-structural protein 13 via helicase-inhibitor-repurposing and non-structural protein 16 through pharmacophore-based screening.
    Samdani MN; Morshed N; Reza R; Asaduzzaman M; Islam ABMMK
    Mol Divers; 2023 Jun; 27(3):1067-1085. PubMed ID: 35690957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review.
    Mohamed K; Yazdanpanah N; Saghazadeh A; Rezaei N
    Bioorg Chem; 2021 Jan; 106():104490. PubMed ID: 33261845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cheminformatics-Based Identification of Potential Novel Anti-SARS-CoV-2 Natural Compounds of African Origin.
    Kwofie SK; Broni E; Asiedu SO; Kwarko GB; Dankwa B; Enninful KS; Tiburu EK; Wilson MD
    Molecules; 2021 Jan; 26(2):. PubMed ID: 33466743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
    Indu P; Rameshkumar MR; Arunagirinathan N; Al-Dhabi NA; Valan Arasu M; Ignacimuthu S
    J Infect Public Health; 2020 Dec; 13(12):1856-1861. PubMed ID: 33168456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-Silico targeting of SARS-CoV-2 NSP6 for drug and natural products repurposing.
    Abdelkader A; Elzemrany AA; El-Nadi M; Elsabbagh SA; Shehata MA; Eldehna WM; El-Hadidi M; Ibrahim TM
    Virology; 2022 Aug; 573():96-110. PubMed ID: 35738174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The SARS-CoV-2 helicase as a target for antiviral therapy: Identification of potential small molecule inhibitors by in silico modelling.
    Pitsillou E; Liang J; Hung A; Karagiannis TC
    J Mol Graph Model; 2022 Jul; 114():108193. PubMed ID: 35462185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting SARS-CoV-2 nsp13 Helicase and Assessment of Druggability Pockets: Identification of Two Potent Inhibitors by a Multi-Site In Silico Drug Repurposing Approach.
    Romeo I; Ambrosio FA; Costa G; Corona A; Alkhatib M; Salpini R; Lemme S; Vergni D; Svicher V; Santoro MM; Tramontano E; Ceccherini-Silberstein F; Artese A; Alcaro S
    Molecules; 2022 Nov; 27(21):. PubMed ID: 36364347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug repurposing for identification of potential spike inhibitors for SARS-CoV-2 using molecular docking and molecular dynamics simulations.
    Lazniewski M; Dermawan D; Hidayat S; Muchtaridi M; Dawson WK; Plewczynski D
    Methods; 2022 Jul; 203():498-510. PubMed ID: 35167916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marine drugs as putative inhibitors against non-structural proteins of SARS-CoV-2: an in silico study.
    Patel S; Hasan H; Umraliya D; Sanapalli BKR; Yele V
    J Mol Model; 2023 May; 29(6):176. PubMed ID: 37171714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.